AMAG Pharmaceuticals Net debt/EBITDA
Mi az AMAG Pharmaceuticals Net debt/EBITDA?
A Net debt/EBITDA az AMAG Pharmaceuticals, Inc. - -5.97
Mi a Net debt/EBITDA meghatározása?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA a Health Care szektor a NASDAQ-on cégekben a AMAG Pharmaceuticals -hoz képest
Mit csinál AMAG Pharmaceuticals?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
net debt/ebitda -hoz hasonló cégek AMAG Pharmaceuticals
- XLMedia PLC nak Net debt/EBITDA -5.99 van
- SEI Investments Co nak Net debt/EBITDA -5.99 van
- Beng Soon Mach Hldg Ltd nak Net debt/EBITDA -5.98 van
- Pacific Silk Road Resources nak Net debt/EBITDA -5.98 van
- Wipro nak Net debt/EBITDA -5.98 van
- MainStreet Bancshares Inc nak Net debt/EBITDA -5.97 van
- AMAG Pharmaceuticals nak Net debt/EBITDA -5.97 van
- Eildon Capital Fund nak Net debt/EBITDA -5.97 van
- CYREN Ltd nak Net debt/EBITDA -5.97 van
- Evolis SA nak Net debt/EBITDA -5.95 van
- Industria de Diseño Textil SA nak Net debt/EBITDA -5.95 van
- VersaBank nak Net debt/EBITDA -5.94 van
- 3P Learning nak Net debt/EBITDA -5.94 van